Seo Danbi, Kim Dain, Kim Wanyeon
Department of Science Education, Korea National University of Education, Cheongju 28173, Korea.
Department of Biology Education, Korea National University of Education, Cheongju 28173, Korea.
Genomics Inform. 2019 Dec;17(4):e36. doi: 10.5808/GI.2019.17.4.e36. Epub 2019 Nov 13.
The incidence and mortality rate of cancer continues to gradually increase, although considerable research effort has been directed at elucidating the molecular mechanisms underlying biomarkers responsible for tumorigenesis. Accumulated evidence indicates that the long non-coding RNAs (lncRNAs), which are transcribed but not translated into functional proteins, contribute to cancer development. Recently, linc00152 (an lncRNA) was identified as a potent oncogene in various cancer types, and shown to be involved in cancer cell proliferation, invasiveness, and motility by sponging tumor-suppressive microRNAs acting as a competing endogenous RNA, binding to gene promoters acting as a transcriptional regulator, and binding to functional proteins. In this review, we focus on the oncogenic role of linc00152 in tumorigenesis and provided an overview of recent clinical studies on the effects of linc00152 expression in human cancers.
尽管在阐明导致肿瘤发生的生物标志物的分子机制方面已经投入了大量的研究工作,但癌症的发病率和死亡率仍在持续逐渐上升。越来越多的证据表明,长链非编码RNA(lncRNA)虽然经过转录但不翻译成功能性蛋白质,却在癌症发展过程中发挥作用。最近,linc00152(一种lncRNA)被确定为多种癌症类型中的强效癌基因,并通过作为竞争性内源RNA来吸附肿瘤抑制性微小RNA、作为转录调节因子与基因启动子结合以及与功能性蛋白质结合,参与癌细胞的增殖、侵袭和迁移。在这篇综述中,我们重点关注linc00152在肿瘤发生中的致癌作用,并概述了近期关于linc00152在人类癌症中表达影响的临床研究。